✦ LIBER ✦

Active specific immunotherapy with tumor cells and Corynebacterium parvum. A phase I study

✍ Scribed by Craig S. McCune; W. Bradford Patterson; Edgar C. Henshaw

Publisher: John Wiley and Sons
Year: 1979
Tongue: English
Weight: 617 KB
Volume: 43
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197905)43:5<1619::aid-cncr2820430509>3.0.co;2-o

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nonspecific immunotherapy by corynebacte

Nonspecific immunotherapy by corynebacterium Parvum. Phase I toxicity study in 12 patients with advanced cancer

✍ Vincent S. T. Cheng; Herman D. Suit; C. C. Wang; Charles Cummings 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 636 KB

Active immunotherapy of human solid tumo

Active immunotherapy of human solid tumor with autologous cells treated with cholesteryl hemisuccinate a phase I study

✍ Yehuda G. Skornick; Guo H. Rong; William F. Sindelar; Lysiane Richert; Joseph M. 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

A randomized study of adjuvant immunothe

A randomized study of adjuvant immunotherapy with levamisole and corynebacterium parvum in operable non-small cell lung cancer

✍ Richard M. Fox; Robert L. Woods; Martin H.N. Tattersall; Antony Basten 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 301 KB

Observations following Corynebacterium p

Observations following Corynebacterium parvum administration to patients with advanced malignancy. A phase I study

✍ Bernard Fisher; Herbert Rubin; George Sartiano; Lana Ennis; Norman Wolmark 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 862 KB

Tumor-specific immunotherapy by active i

Tumor-specific immunotherapy by active immunization with haptenic muramyl dipeptide (MDP) derivative-coupled tumor cells

✍ J. Shima; H. Sano; A. Kosugi; H. Fujiwara; T. Hamaoka 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Specific active immunotherapy in patient

Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial

✍ Ariel Hollinshead; E. George Elias; Myron Arlen; Barbara Buda; Maria Mosley; Jos 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 838 KB

Twenty-two patients received specific active immunotherapy (TAA vaccine once per month for 3 months), with the duration of follow-up, as of July 1984, ranging from 3 months to 36 months (median, 21 months). Of these, seven had Dukes Bz, seven had Dukes C, and eight had Dukes D lesions. All received